Innovation Pharmaceuticals received pre-IND response from FDA on COVID-19 trial
On Nov. 2, 2020, Innovation Pharma announced receipt of written feedback from the FDA that is in general…
-
-
Kaiser Permanente Research Institute enrolled volunteers in a phase 3 clinical trial to evaluate COVID-19 vaccine
On Oct. 30, 2020, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced enrollment of volunteers in a phase…
-
Icosavax launched COVID-19 vaccine program with preclinical data and $165 million in new funding
On Oct. 30, 2020, Icosavax announced the launch of the companyﾒs COVID-19 vaccine program with preclinical data on…
-
Moderna partnered with Takeda and Government of Japan to supply 50 million doses of mRNA vaccine against COVID-19
On Oct. 29, 2020, Takeda Pharmaceutical announced that it would import and distribute 50 million doses of Moderna’s…
-
Global clinical trials of COVID-19 vaccine resumed
On Oct. 23, 2020, the U.S. FDA authorised a restart of clinical trials of the ChAdOx1 nCov-2019 Oxford…
-
FDA authorised restart of the COVID-19 AZD1222 vaccine US phase III trial
On Oct. 23, 2020, AstraZeneca announced that the clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, had…
-
Roche announced collaboration with Atea Pharmaceuticals to develop potential oral treatment for COVID-19 patients
On Oct. 22, 2020, Roche and Atea Pharmaceuticals announced they had joined forces in the fight against COVID-19…
-
Scientists used gene therapy and a novel light-sensing protein to restore vision in mice
On Oct. 22, 2020, a newly developed light-sensing protein called the MCO1 opsin restored vision in blind mice…
-
Landmark TB trial identified shorter-course treatment regimen
On Oct. 21, 2020, results from an international, randomized, controlled clinical trial indicated that a four-month daily treatment…
-
ImmunityBio, NantKwest announced first patient dosed in phase 1 clinical trial of second-generation COVID-19 vaccine candidate
On Oct. 21, 2020, ImmunityBio and NantKwest announced that the first patient had been dosed in the Phase…
-
Mateon’s phase 2 global study for OT-101/ TGF- Inhibitor against COVID-19 cleared for patient enrollment in Argentina
On Oct. 19, 2020, Mateon Therapeutics announced the receipt of approval from Republica Argentina Poder Ejecutivo Nacional, the…
-
LabCorp launched quantitative antibody test to assess effectiveness ef COVID-19 vaccines in clinical trials
On Oct. 19, 2020, LabCorp announced a test that provided a quantitative measurement of an individualﾒs SARS-CoV-2 IgG…
-
NIH began large clinical trial to test immune modulators for treatment of COVID-19
On Oct. 16, 2020, the NIH launched an adaptive Phase 3 clinical trial to evaluate the safety and…
-
FDA authorized phase 1 trial of ImmunityBioﾒs novel COVID-19 vaccine candidate hAd5 to drive T cell and antibody immunity
On Oct. 15, 2020, ImmunityBio announced it had received authorization from the FDA to begin a Phase I…
-
Brazilian Health Regulatory Agency authorized Sorrento’s phase 2 clinical trial of Abivertinib in COVID-19 patients
On Oct. 14, 2020, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed…
-
Vaxart announced positive hamster challenge study data for its oral COVID-19 vaccine
On Oct. 14, 2020, Vaxart announced that the FDA had completed its review of the Companyﾒs Investigational New…
-
COVID-19 vaccine with Dynavaxﾒs CpG 1018 adjuvant received Taiwan government subsidy with first dosage
On Oct. 13, 2020, Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced that MVC had obtained a Taiwan…
-
NIH study to identify promising COVID-19 treatments for larger clinical trials
On Oct. 13, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), launched a study designed to…
-
NeoGenomics expanded global footprint in pharma services with new clinical research laboratory in Suzhou, China
On Oct. 13, 2020, NeoGenomics announced plans to open a state-of-the-art research laboratory in China in association with…
-
Eli Lilly paused trial of antibody drug Trump touted as COVID-19 ‘cure’ over safety concern
On Oct. 13, 2020, Eli Lilly announced that the government-sponsored clinical trial of its COVID-19 antibody treatment similar…
-
Johnson & Johnson temporarily paused all dosing in Janssen COVID-19 vaccine candidate clinical trials
On Oct. 12, 2020, Johnson & Johnson announced temporarily paused further dosing in all our COVID-19 vaccine candidate…
-
NIH clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
-
FDA awarded grants to fund clinical trials to advance development of products for treatment of rare diseases
On Oct. 8, 2020, the FDA announced that it had awarded six new clinical trial research grants to…
-
Emergent BioSolutionsﾒ COVID-19 product candidate included in NIH-sponsored phase 3 clinical trial
On Oct. 8, 2020, Emergent BioSolutions announced the initiation of the Phase 3 clinical trial that will evaluate…
-
Caladrius Biosciences opened study of CLBS119 to repair COVID-19-induced lung damage
On Oct. 8, 2020, Caladrius Biosciences announced that it had opened its proof-of-concept study of CLBS119 as a…
-
NIAID clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
-
Rentschler Biopharma contributed to manufacturing of COVID-19 mRNA vaccine
On Oct. 7, 2020, Rentschler Biopharma announced an agreement to serve as CDMO partner for BioNTech. As an…
-
Lilly updated progress of SARS-CoV-2 neutralizing antibody programs
On Oct. 7, 2020, Eli Lilly announced additional details on its SARS-CoV-2 neutralizing antibody programs ﾖ including interim…
-
HHS funded development of needle-free vaccine administration technology
On Oct. 6, 2020, the U.S. Department of Health and Human Services (HHS) announced funding of a patch…
-
AIM ImmunoTech announced approval to enroll COVID-19 ‘long haulers’ in AMP-511 ME/CFS clinical trial of Ampligen
On Oct. 6, 2020, AIM ImmunoTech announced that it had received Institutional Review Board approval for the expansion…
